BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Daiichi Sankyo
Cantor Fitzgerald

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020857

« Back to Dashboard
NDA 020857 describes COMBIVIR, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from five suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the COMBIVIR profile page.

The generic ingredient in COMBIVIR is lamivudine; zidovudine. There are twenty-seven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.

Summary for NDA: 020857

Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 020857

Suppliers and Packaging for NDA: 020857

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
lamivudine; zidovudine
TABLET;ORAL 020857 NDA Stat Rx USA 16590-061 16590-061-10 10 TABLET, FILM COATED in 1 BOTTLE (16590-061-10)
lamivudine; zidovudine
TABLET;ORAL 020857 NDA Stat Rx USA 16590-061 16590-061-30 30 TABLET, FILM COATED in 1 BOTTLE (16590-061-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG;300MG
Approval Date:Sep 26, 1997TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Nov 18, 2016Product Flag?Substance Flag?Delist Request?

Expired Orange Book Patents for NDA: 020857

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Express Scripts
Harvard Business School
Daiichi Sankyo
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus